The management of secondary osteoporosis

Ariella Kelman, Nancy E Lane

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Secondary osteoporosis is common among patients being evaluated for osteoporosis. All men and premenopausal women with unexplained bone loss or a history of a fragility fracture should undergo a work-up for secondary osteoporosis. Also, postmenopausal women with risk factors for secondary osteoporosis should be carefully evaluated. The evaluation should include a thorough history, physical examination, bone mineral density testing, and laboratory testing. While there is no consensus for a cost-effective laboratory evaluation, some recommendations include: 25-hydroxyvitamin D, parathyroid hormone (PTH), serum and urine calcium, phosphate, creatinine, liver function tests, a complete blood count, testosterone in men, and thyroid-stimulating hormone. After a thorough review of the evaluation for secondary osteoporosis, this chapter reviews the pathophysiology and treatment of secondary osteoporotic disorders, including vitamin D insufficiency, osteomalacia, the osteoporosis of erosive inflammatory arthritis, ankylosing spondylitis, systemic lupus erythematosus, and osteoporosis related to anti-androgenic therapy for prostate cancer and aromatase inhibitor therapy for breast cancer. Physicians have a significant responsibility to evaluate and treat the underlying medical problem that is the cause of secondary osteoporosis and to optimize bone health in the individual patient.

Original languageEnglish (US)
Pages (from-to)1021-1037
Number of pages17
JournalBest Practice and Research: Clinical Rheumatology
Volume19
Issue number6
DOIs
StatePublished - Dec 2005

Fingerprint

Osteoporosis
Bone and Bones
Osteomalacia
Aromatase Inhibitors
Blood Cell Count
Liver Function Tests
Ankylosing Spondylitis
Thyrotropin
Parathyroid Hormone
Vitamin D
Systemic Lupus Erythematosus
Bone Density
Physical Examination
Arthritis
Testosterone
Creatinine
Prostatic Neoplasms
Therapeutics
History
Urine

Keywords

  • Androgen deprivation therapy
  • Ankylosing spondylitis
  • Aromatase inhibitors
  • Glucocorticoids
  • Lupus
  • Osteomalacia
  • Osteonecrosis
  • Rheumatoid arthritis
  • Secondary osteoporosis
  • Vitamin D deficiency

ASJC Scopus subject areas

  • Orthopedics and Sports Medicine
  • Rheumatology

Cite this

The management of secondary osteoporosis. / Kelman, Ariella; Lane, Nancy E.

In: Best Practice and Research: Clinical Rheumatology, Vol. 19, No. 6, 12.2005, p. 1021-1037.

Research output: Contribution to journalArticle

@article{82bca2061a20449eb05d6d273fbeed2f,
title = "The management of secondary osteoporosis",
abstract = "Secondary osteoporosis is common among patients being evaluated for osteoporosis. All men and premenopausal women with unexplained bone loss or a history of a fragility fracture should undergo a work-up for secondary osteoporosis. Also, postmenopausal women with risk factors for secondary osteoporosis should be carefully evaluated. The evaluation should include a thorough history, physical examination, bone mineral density testing, and laboratory testing. While there is no consensus for a cost-effective laboratory evaluation, some recommendations include: 25-hydroxyvitamin D, parathyroid hormone (PTH), serum and urine calcium, phosphate, creatinine, liver function tests, a complete blood count, testosterone in men, and thyroid-stimulating hormone. After a thorough review of the evaluation for secondary osteoporosis, this chapter reviews the pathophysiology and treatment of secondary osteoporotic disorders, including vitamin D insufficiency, osteomalacia, the osteoporosis of erosive inflammatory arthritis, ankylosing spondylitis, systemic lupus erythematosus, and osteoporosis related to anti-androgenic therapy for prostate cancer and aromatase inhibitor therapy for breast cancer. Physicians have a significant responsibility to evaluate and treat the underlying medical problem that is the cause of secondary osteoporosis and to optimize bone health in the individual patient.",
keywords = "Androgen deprivation therapy, Ankylosing spondylitis, Aromatase inhibitors, Glucocorticoids, Lupus, Osteomalacia, Osteonecrosis, Rheumatoid arthritis, Secondary osteoporosis, Vitamin D deficiency",
author = "Ariella Kelman and Lane, {Nancy E}",
year = "2005",
month = "12",
doi = "10.1016/j.berh.2005.06.005",
language = "English (US)",
volume = "19",
pages = "1021--1037",
journal = "Best Practice and Research in Clinical Rheumatology",
issn = "1521-6942",
publisher = "Bailliere Tindall Ltd",
number = "6",

}

TY - JOUR

T1 - The management of secondary osteoporosis

AU - Kelman, Ariella

AU - Lane, Nancy E

PY - 2005/12

Y1 - 2005/12

N2 - Secondary osteoporosis is common among patients being evaluated for osteoporosis. All men and premenopausal women with unexplained bone loss or a history of a fragility fracture should undergo a work-up for secondary osteoporosis. Also, postmenopausal women with risk factors for secondary osteoporosis should be carefully evaluated. The evaluation should include a thorough history, physical examination, bone mineral density testing, and laboratory testing. While there is no consensus for a cost-effective laboratory evaluation, some recommendations include: 25-hydroxyvitamin D, parathyroid hormone (PTH), serum and urine calcium, phosphate, creatinine, liver function tests, a complete blood count, testosterone in men, and thyroid-stimulating hormone. After a thorough review of the evaluation for secondary osteoporosis, this chapter reviews the pathophysiology and treatment of secondary osteoporotic disorders, including vitamin D insufficiency, osteomalacia, the osteoporosis of erosive inflammatory arthritis, ankylosing spondylitis, systemic lupus erythematosus, and osteoporosis related to anti-androgenic therapy for prostate cancer and aromatase inhibitor therapy for breast cancer. Physicians have a significant responsibility to evaluate and treat the underlying medical problem that is the cause of secondary osteoporosis and to optimize bone health in the individual patient.

AB - Secondary osteoporosis is common among patients being evaluated for osteoporosis. All men and premenopausal women with unexplained bone loss or a history of a fragility fracture should undergo a work-up for secondary osteoporosis. Also, postmenopausal women with risk factors for secondary osteoporosis should be carefully evaluated. The evaluation should include a thorough history, physical examination, bone mineral density testing, and laboratory testing. While there is no consensus for a cost-effective laboratory evaluation, some recommendations include: 25-hydroxyvitamin D, parathyroid hormone (PTH), serum and urine calcium, phosphate, creatinine, liver function tests, a complete blood count, testosterone in men, and thyroid-stimulating hormone. After a thorough review of the evaluation for secondary osteoporosis, this chapter reviews the pathophysiology and treatment of secondary osteoporotic disorders, including vitamin D insufficiency, osteomalacia, the osteoporosis of erosive inflammatory arthritis, ankylosing spondylitis, systemic lupus erythematosus, and osteoporosis related to anti-androgenic therapy for prostate cancer and aromatase inhibitor therapy for breast cancer. Physicians have a significant responsibility to evaluate and treat the underlying medical problem that is the cause of secondary osteoporosis and to optimize bone health in the individual patient.

KW - Androgen deprivation therapy

KW - Ankylosing spondylitis

KW - Aromatase inhibitors

KW - Glucocorticoids

KW - Lupus

KW - Osteomalacia

KW - Osteonecrosis

KW - Rheumatoid arthritis

KW - Secondary osteoporosis

KW - Vitamin D deficiency

UR - http://www.scopus.com/inward/record.url?scp=28644451831&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28644451831&partnerID=8YFLogxK

U2 - 10.1016/j.berh.2005.06.005

DO - 10.1016/j.berh.2005.06.005

M3 - Article

C2 - 16301195

AN - SCOPUS:28644451831

VL - 19

SP - 1021

EP - 1037

JO - Best Practice and Research in Clinical Rheumatology

JF - Best Practice and Research in Clinical Rheumatology

SN - 1521-6942

IS - 6

ER -